MERIDIAN BIOSCIENCE, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 17 rows in 2022. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2022-06-27: Reporting owner Kenny John P.; Form 4; Security Stock Options (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2022-06-24: Reporting owner Kenny John P.; Form 4; Security Stock Options (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2022-06-23: Reporting owner Kenny John P.; Form 4; Security Stock Options (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2022-06-23: Reporting owner Kenny John P.; Form 4; Security Stock Options (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2022-06-27 | Kenny John P. Director, Officer (Chief Executive Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −61,437 66,039 owned after | $10.10 exercise price | 2022-06-28 | |
| 2022-06-24 | Kenny John P. Director, Officer (Chief Executive Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,559 127,476 owned after | $10.10 exercise price | 2022-06-28 | |
| 2022-06-23 | Kenny John P. Director, Officer (Chief Executive Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,349 0 owned after | $14.50 exercise price | 2022-06-24 | |
| 2022-06-23 | Kenny John P. Director, Officer (Chief Executive Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −14,607 141,035 owned after | $10.10 exercise price | 2022-06-24 | |
| 2022-06-22 | Kenny John P. Director, Officer (Chief Executive Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −44,651 5,349 owned after | $14.50 exercise price | 2022-06-24 | |
| 2022-02-21 | Kitzmiller Andrew S. Officer (EVP & CFO) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,000 5,000 owned after | $24.74 exercise price | 2022-02-22 | |
| 2022-02-15 | WELTZIEN LOURDES Officer (EVP, Life Science) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −12,500 0 owned after | $14.65 exercise price | 2022-02-17 | |
| 2022-02-15 | WELTZIEN LOURDES Officer (EVP, Life Science) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,500 2,500 owned after | $14.30 exercise price | 2022-02-17 | |
| 2022-01-26 | Williams Felicia Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,656 5,656 owned after | $20.75 exercise price | 2022-01-28 | |
| 2022-01-26 | Sazdanoff Catherine Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,656 5,656 owned after | $20.75 exercise price | 2022-01-28 | |
| 2022-01-26 | Rice John McCune Jr. Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,656 5,656 owned after | $20.75 exercise price | 2022-01-28 | |
| 2022-01-26 | McIlwraith John Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,656 5,656 owned after | $20.75 exercise price | 2022-01-28 | |
| 2022-01-26 | Ellingwood Dwight E Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,656 5,656 owned after | $20.75 exercise price | 2022-01-28 | |
| 2022-01-26 | Bihl Anthony P III Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,656 5,656 owned after | $20.75 exercise price | 2022-01-28 | |
| 2022-01-26 | Anderson James M. Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,656 5,656 owned after | $20.75 exercise price | 2022-01-28 | |
| 2022-01-12 | PHILLIPS DAVID Director | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,500 0 owned after | $18.54 exercise price | 2022-01-14 | |
| 2022-01-03 holding as of filing | Smith Julie Diana Officer (Sr VP, Controller, PAO) | 3 | Option to Buy Derivative · Direct | Holding | $6.97 exercise price | 2022-01-03 |